Richard Pazdur, the newly installed head of the FDA’s Center for Drug Evaluation and Research, filed paperwork to retire at month‑end, compounding turnover at the agency’s senior ranks. The development follows other high‑profile leadership moves inside the FDA and comes as the agency confronts contentious internal debates over vaccine policy and review standards. Separately, the FDA named Tracy Beth Høeg as acting director of CDER’s drug center, a move that continues rapid leadership changes and will shape review priorities in the near term. The personnel shifts were reported in public filings and agency announcements and have prompted concern among industry stakeholders about continuity in regulation.